Welcome to our dedicated page for Compugen news (Ticker: CGEN), a resource for investors and traders seeking the latest updates and insights on Compugen stock.
Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage biopharmaceutical pioneer leveraging computational discovery to advance novel cancer immunotherapies. This news hub provides investors and researchers with timely updates on clinical trials, strategic partnerships, and therapeutic innovations emerging from Compugen's AI-driven platform.
Access authoritative updates on key developments including COM701 (anti-PVRIG), COM902 (anti-TIGIT), and collaborative programs with industry leaders. Our curated news collection simplifies tracking of pipeline progress, peer-reviewed research publications, and milestone achievements in immuno-oncology.
Content spans clinical trial results, regulatory milestones, and partner collaboration updates, offering a comprehensive view of Compugen's position in next-generation cancer treatment development. Bookmark this page for streamlined access to verified information about therapeutic candidates and computational discovery breakthroughs.
Compugen (NASDAQ: CGEN) has announced the enhancement of its AI/ML predictive computational discovery platform, Unigen™, through collaboration with Ultima Genomics' single cell sequencing technology. The partnership combines Compugen's platform with Ultima's UG 100™ sequencing platform to gain deeper insights into tumor biology and immune regulation.
Key findings presented at the AGBT 2025 General Meeting revealed high consistency in single-cell expression levels between Ultima's UG 100 and Illumina's Novaseq 6000 platforms. The UG 100 demonstrated superior capability in identifying 3' mRNA transcript endings, potentially advancing the understanding of gene structure in tumor biology.
The collaboration aims to leverage Ultima's technology for developing proprietary single cell atlases to accelerate new immunotherapy discoveries. The research findings contribute to Unigen's predictive models, with potential applications in developing new cancer immunotherapies.
Compugen (CGEN) has announced it will release its fourth quarter and full year 2024 financial results on Tuesday, March 4, 2025, before U.S. markets open. The clinical-stage cancer immunotherapy company will host a conference call and webcast at 8:30 am ET, where management will review financial results and provide a corporate update.
Investors can access the conference call by dialing 1-866-744-5399 from the U.S. or +972-3-918-0644 internationally. A live webcast will be available through Compugen's website, with a replay accessible afterward.
Compugen (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company specializing in computational target discovery, has announced its upcoming participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference. The company's management will engage in a fireside chat during the virtual conference on February 11, 2025, at 8am ET.
Investors and interested parties can access a live webcast of the presentation through the Investor Relations section of Compugen's website at www.cgen.com. For those unable to attend the live session, a replay will be made available after the event.
AstraZeneca and Daiichi Sankyo have initiated the TROPION-Lung12 Phase 3 trial, dosing their first patient to evaluate DATROWAY® (datopotamab deruxtecan) plus rilvegostomig or rilvegostomig monotherapy versus standard of care. The trial targets patients with stage 1 adenocarcinoma non-small cell lung cancer (NSCLC) after complete surgical resection who are ctDNA-positive or have high-risk pathological features.
Currently, stage 1 NSCLC treatment involves tumor resection, but up to 40% of patients may experience disease recurrence. While observation typically follows resection, adjuvant chemotherapy and/or immunotherapy may be offered to high-risk stage 1b patients. The trial aims to explore DATROWAY's potential role in combination with immunotherapy as an adjuvant treatment to prevent disease recurrence.
Compugen (NASDAQ: CGEN) has announced the dosing of its first patient in a Phase 1 clinical trial for COM503, a potential first-in-class antibody against IL-18 binding protein licensed to Gilead Sciences. The multi-center trial will evaluate COM503's safety, tolerability, and pharmacokinetics both as a monotherapy and in combination with Gilead's anti-PD1, zimberelimab, in patients with advanced solid tumors.
The trial, initiated in Q4 2024, represents a new approach to cancer treatment through cytokine biology. Compugen's Unigen™ discovery engine identified high IL-18 expression in cancer patients' tumors, but found its anti-tumor activity is blocked by an endogenous IL-18-binding protein. COM503 works by blocking this protein, potentially enabling naturally occurring IL-18 to fight cancer within tumors, addressing limitations of systemic cytokine administration.
The first patient was dosed at the START Center for Cancer Research-Midwest in Grand Rapids, Michigan, with Compugen responsible for conducting the Phase 1 trial.
Compugen (NASDAQ: CGEN) has been granted a new U.S. patent (No. 12152084) covering the triple combination use of its COM902 anti-TIGIT antibody with anti-PD-1 and anti-PVRIG antibodies for cancer treatment. The patent strengthens Compugen's IP portfolio and protects the use of COM902, a reduced Fc clinical-stage antibody, in combination with any anti-PD-1 and anti-PVRIG antibodies. The patent is set to expire no earlier than August 2037.
The company highlights that recent developments suggest potential advantages of anti-TIGITs without active Fc binder, like COM902. Their data indicates blocking TIGIT alone may be insufficient for optimal anti-tumor activity in certain cases, particularly in tumors non-responsive to PD-1 inhibition.
Compugen (NASDAQ: CGEN) reported Q3 2024 financial results and corporate updates. The company presented clinical data for COM701 at SITC 2024, showing durable responses in immunotherapy-resistant tumors. Plans include initiating an adaptive platform trial for COM701 in Q2 2025 for ovarian cancer patients. The company reported $17.1 million in revenues and a net profit of $1.3 million for Q3 2024. Cash position stands at $113.2 million, expected to fund operations into 2027. Partner AstraZeneca advanced rilvegostomig into additional Phase 3 trials, while COM503's Phase 1 trial is set to begin in Q4 2024.
Compugen (Nasdaq: CGEN) announced its participation in the Stifel 2024 Healthcare Conference in New York City. The company's management will engage in a fireside chat scheduled for Monday, November 18, 2024, at 8:35 am ET. The event will be accessible through a live webcast on the Investor Relations section of Compugen's website, with a replay available after the event. Compugen, operating as a clinical-stage cancer immunotherapy company, is known for its pioneering work in computational target discovery.
Compugen (CGEN) has announced promising data on the triple combination of COM701, COM902, and pembrolizumab in treating platinum-resistant ovarian cancer patients. The data will be presented at the SITC 2024 conference in Houston, Texas. The study showed a 17.4% confirmed objective response rate and a 43.5% disease control rate in 23 evaluable patients.
The treatment demonstrated a favorable safety profile with mostly Grade 2 or lower adverse events, and only one Grade 3 event reported. Dr. Oladapo Yeku from Harvard Medical School highlighted the treatment's durability and effectiveness in late-stage ovarian cancer patients. The company plans to advance COM701 to earlier stages of ovarian cancer therapy, particularly targeting patients who are ineligible for maintenance treatment.
Daiichi Sankyo and AstraZeneca have initiated three global Phase 3 trials evaluating datopotamab deruxtecan (Dato-DXd) combinations in advanced nonsquamous non-small cell lung cancer (NSCLC). The trials include: TROPION-Lung10 testing Dato-DXd plus rilvegostomig in high PD-L1 expression patients; TROPION-Lung14 evaluating Dato-DXd plus osimertinib in EGFR mutated NSCLC; and TROPION-Lung15 studying Dato-DXd with/without osimertinib in EGFR mutated NSCLC that progressed on osimertinib. These trials are part of the expanding TROPION program, which now includes seven Phase 3 trials.
FAQ
What is the current stock price of Compugen (CGEN)?
What is the market cap of Compugen (CGEN)?
